
Overview
Background
Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).
Availability
- Dr Andy Moore is:
- Not available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
- Doctor of Philosophy, University College London
Research interests
-
Acute Myeloid Leukaemia
-
Leukaemia
-
Blood Cancers
-
Paediatric Oncology
-
Childhood Cancer
-
Biobanking
Works
Search Professor Andy Moore’s works on UQ eSpace
2017
Journal Article
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia
Charmsaz, S., Al-Ejeh, F., Yeadon, T. M., Miller, K. J., Smith, F. M., Stringer, B. W., Moore, A. S., Lee, F.-T., Cooper, L. T., Stylianou, C., Yarranton, G. T., Woronicz, J., Scott, A. M., Lackmann, M. and Boyd, A. W. (2017). EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia, 31 (8), 1779-1787. doi: 10.1038/leu.2016.371
2016
Journal Article
Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors
Torchia, Jonathon, Golbourn, Brian, Feng, Shengrui, Ho, King Ching, Sin-Chan, Patrick, Vasiljevic, Alexandre, Norman, Joseph D., Guilhamon, Paul, Garzia, Livia, Agamez, Natalia R., Lu, Mei, Chan, Tiffany S., Picard, Daniel, de Antonellis, Pasqualino, Khuong-Quang, Dong-Anh, Planello, Aline C., Zeller, Constanze, Barsyte-Lovejoy, Dalia, Lafay-Cousin, Lucie, Letourneau, Louis, Bourgey, Mathieu, Yu, Man, Gendoo, Deena M. A., Dzamba, Misko, Barszczyk, Mark, Medina, Tiago, Riemenschneider, Alexandra N., Morrissy, A. Sorana, Ra, Young-Shin ... Huang, Annie (2016). Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell, 30 (6), 891-908. doi: 10.1016/j.ccell.2016.11.003
2016
Journal Article
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D. and Vormoor, J. (2016). A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood and Cancer, 64 (6) e26351, e26351. doi: 10.1002/pbc.26351
2016
Journal Article
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Smith, Amanda M., Dun, Matthew D., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan, Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop and Verrills, Nicole M. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7 (30), 47465-47478. doi: 10.18632/oncotarget.10167
2016
Journal Article
Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
Nikbakht, Hamid, Panditharatna, Eshini, Mikael, Leonie G., Li, Rui, Gayden, Tenzin, Osmond, Matthew, Ho, Cheng-Ying, Kambhampati, Madhuri, Hwang, Eugene I., Faury, Damien, Siu, Alan, Papillon-Cavanagh, Simon, Bechet, Denise, Ligon, Keith L., Ellezam, Benjamin, Ingram, Wendy J., Stinson, Caedyn, Moore, Andrew S., Warren, Katherine E., Karamchandani, Jason, Packer, Roger J., Jabado, Nada, Majewski, Jacek and Nazarian, Javad (2016). Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 7 (1) 11185, 11185. doi: 10.1038/ncomms11185
2016
Journal Article
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
Thompson, Eric M., Hielscher, Thomas, Bouffet, Eric, Remke, Marc, Luu, Betty, Gururangan, Sridharan, McLendon, Roger E., Bigner, Darell D., Lipp, Eric S., Perreault, Sebastien, Cho, Yoon-Jae, Grant, Gerald, Kim, Seung-Ki, Lee, Ji Yeoun, Rao, Amulya A. Nageswara, Giannini, Caterina, Li, Kay Ja Wai, Ng, Ho-Keung, Yao, Yu, Kumabe, Toshihiro, Tominaga, Teiji, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Low, David C. Y., Seow, Wan Tew, Chang, Kenneth T. E., Mora, Jaume, Pollack, Ian F., Hamilton, Ronald L. ... Taylor, Michael D. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology, 17 (4), 484-495. doi: 10.1016/S1470-2045(15)00581-1
2016
Journal Article
New brain tumor entities emerge from molecular classification of CNS-PNETs
Sturm, Dominik, Orr, Brent A., Toprak, Umut H., Hovestadt, Volker, Jones, David T. W., Capper, David, Sill, Martin, Buchhalter, Ivo, Northcott, Paul A., Leis, Irina, Ryzhova, Marina, Koelsche, Christian, Pfaff, Elke, Allen, Sariah J., Balasubramanian, Gnanaprakash, Worst, Babara C., Pajtler, Kristian W., Brabetz, Sebastian, Johann, Pascal D., Sahm, Felix, Reimand, Juri, Mackay, Alan, Carvalho, Diana M., Remke, Marc, Phillips, Joanna J., Perry, Arie, Cowdrey, Cynthia, Drissi, Rachid, Fouladi, Maryam ... Kool, Marcel (2016). New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell, 164 (5), 1060-1072. doi: 10.1016/j.cell.2016.01.015
2016
Conference Publication
A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer.
Hennig, S., Kunarajah, K., Norris, R., Lobb, M., Charles, B., Pinkerton, R. and Moore, A. S. (2016). A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer.. World Conference of Pharmacometrics, Brisbane / Brisbane Convention Centre, 21-24 August 2016.
2015
Journal Article
EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.
Charmsaz, Sara, Beckett, Kirrilee, Smith, Fiona M., Bruedigam, Claudia, Moore, Andrew S., Al-Ejeh, Fares, Lane, Steven W. and Boyd, Andrew W. (2015). EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.. PLoS One, 10 (6) e0130692, e0130692-e0130692. doi: 10.1371/journal.pone.0130692
2015
Journal Article
The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.
Foresto, Steven A., Youlden, Danny R., Baader, Peter D., Hallahan, Andrew R., Aitken, Joanne F. and Moore, Andrew S. (2015). The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.. Pediatric Blood and Cancer, 62 (9), 1664-1666. doi: 10.1002/pbc.25517
2015
Journal Article
Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia
Smith, Amanda M., Little, Erica B., Zivanovic, Andjelija, Hong, Priscilla, Liu, Alfred K. S., Burow, Rachel, Stinson, Caedyn, Hallahan, Andrew R. and Moore, Andrew S. (2015). Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia. Leukemia Research, 39 (4), 435-444. doi: 10.1016/j.leukres.2015.01.005
2015
Conference Publication
Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome
Hahn, Christopher N., Babic, Milena, Schreiber, Andreas W., Kutyna, Monika M., Wee, L. Amilia, Brown, Anna L., Perugini, Michelle, Singhal, Deepak, Hiwase, Smita, Feng, Jinghua, Parker, Wendy T., Moore, Sarah, Bardy, Peter G., Saal, Russell, Marlton, Paula, Moore, Andrew S., Gonda, Thomas J., Leo, Paul, Branford, Susan, DAndrea, Richard J., Lewis, Ian D., Bik, Luen, Scott, Harnish S. and Hiwase, Devendra (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 5-8 December 2015. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood.V126.23.1644.1644
2014
Journal Article
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy
Bruedigam, C., Bagger, F.O., Heidel, F.H., Paine, Kuhn C., Guignes, S., Song, A., Austin, R., Vu, T., Lee, E., Riyat, S., Moore, A.S., Lock, R.B., Bullinger, L., Hill, G.R., Armstrong, S.A., Williams, D.A. and Lane, S.W. (2014). Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell, 15 (6), 775-790. doi: 10.1016/j.stem.2014.11.010
2014
Journal Article
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
Roberts, K. G., Li, Y., Payne‑Turner, D., Harvey, R. C., Yang, Y.‑L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., Ma, J., Becksfort, J., Rusch, M., Chen, S.‑C., Easton, J., Cheng, J., Boggs, K., Santiago‑Morales, N., Iacobucci, I., Fulton, R. S., Wen, J., Valentine, M., Cheng, C., Paugh, S. W., Devidas, M., Chen, I.‑M., Reshmi, S., Smith, A., Hedlund, E. ... Mullighan, C. G. (2014). Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine, 371 (11), 1005-1015. doi: 10.1056/NEJMoa1403088
2014
Conference Publication
Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)
Bruedigam, Claudia, Bagger, Frederik Otzen, Heidel, Florian H., Kuhn, Catherine, Guignes, Solene, Song, Axia, Austin, Rebecca, Vu, Therese, Lee, Erwin M., Moore, Andrew S., Lock, Richard B., Bullinger, Lars, Hill, Geoff R. and Lane, Steven W. (2014). Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML). 56th Annual Meeting of the American Society of Hematology, San Francisco CA, United States, 06-09 December 2014. Washington, DC United States: American Society of Hematology.
2013
Journal Article
Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
Soosay Raj, Trisha A., Smith, Amanda M. and Moore, Andrew S. (2013). Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. International Journal of Nanomedicine, 8 (1), 4361-4369. doi: 10.2147/IJN.S54657
2013
Journal Article
BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
Moore, Andrew S., Alonzo, Todd A., Gerbing, Robert B., Lange, Beverly J., Heerema, Nyla A., Franklin, Janet, Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S. and Meshinchi, Soheil (2013). BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood and Cancer, 61 (4), 647-652. doi: 10.1002/pbc.24822
2013
Journal Article
Novel therapies for children with acute myeloid leukaemia
Moore, A. S., Kearns, P. R., Knapper, S., Pearson, A. D. J. and Zwaan, C. M. (2013). Novel therapies for children with acute myeloid leukaemia. Leukemia, 27 (7), 1451-1460. doi: 10.1038/leu.2013.106
2012
Journal Article
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia
Bavetsias, Vassilios, Crumpler, Simon, Sun, Chongbo, Avery, Sian, Atrash, Butrus, Faisal, Amir, Moore, Andrew S., Kosmopoulou, Magda, Brown, Nathan, Sheldrake, Peter W., Bush, Katherine, Henley, Alan, Box, Gary, Valenti, Melanie, Brandon, Alexis de Haven, Raynaud, Florence I., Workman, Paul, Eccles, Suzanne A., Bayliss, Richard, Linardopoulos, Spiros and Blagg, Julian (2012). Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 55 (20), 8721-8734. doi: 10.1021/jm300952s
2012
Journal Article
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns
Moore, A. S., Faisal, A., Gonzalez de Castro, D., Bavetsias, V., Sun, C., Atrash, B., Valenti, M., de Haven Brandon, A., Avery, S., Mair, D., Mirabella, F., Swansbury, J., Pearson, A. D. J., Workman, P., Blagg, J., Raynaud, F. I., Eccles, S. A. and Linardopoulos, S. (2012). Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns. Leukemia, 26 (7), 1462-1470. doi: 10.1038/leu.2012.52
Supervision
Availability
- Dr Andy Moore is:
- Not available for supervision
Supervision history
Completed supervision
-
2020
Doctor Philosophy
Characterisation of the MLL fusion transcriptome in childhood leukaemia
Principal Advisor
-
Doctor Philosophy
Aminopeptidase Inhibition as a Potential Therapeutic Strategy for Acute Myeloid Leukaemia
Principal Advisor
Media
Enquiries
Contact Dr Andy Moore directly for media enquiries about:
- Childhood Cancer
- Childhood Leukaemia
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: